← Back to Screener
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL)
Price$0.70
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (4W)-35.78%
VGM Score13.36
All Metrics
Price vs S&P 500 (YTD)-31.29%
10-Day Avg Trading Volume0.03M
3-Month Avg Trading Volume0.03M
52-Week High$1.40
13-Week Price Return-34.19%
3-Month Return Std Dev110.85%
Year-to-Date Return-24.74%
5-Day Price Return-16.19%
Month-to-Date Return-26.33%
Price vs S&P 500 (13W)-42.44%
52-Week Low$0.65
mGradeF
vgmGradeF
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCTXLBriaCell Therapeutics Corp. Warrant expiring 2031 | — | — | F | $0.70 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
BriaCell Therapeutics is a clinical-stage biotechnology company developing cell-based immunotherapies for cancer. Its lead program, Bria-IMT, is in end-stage clinical trials for breast cancer, while pipeline candidate Bria-OTS targets breast and prostate cancer with personalized approaches. The company is pursuing combination therapy strategies through clinical collaborations to enhance treatment outcomes.